About the Product

Description


Ondotyle Injection, containing Ondansetron (2mg), is a fast-acting antiemetic designed to prevent and treat nausea and vomiting in various medical situations. Ondansetron, a selective serotonin (5-HT3) receptor antagonist, works by blocking the action of serotonin in the brain and gastrointestinal tract, which are key triggers for nausea and vomiting. This makes it highly effective for use during chemotherapy, radiotherapy, and after surgical procedures, where these symptoms are common.

Ondotyle Injection is administered intravenously or intramuscularly, ensuring rapid action and providing relief when oral administration is not feasible. Its targeted mechanism of action and reliable efficacy make it a preferred choice for healthcare professionals in managing acute and severe cases of nausea and vomiting.

Common side effects may include headache, dizziness, constipation, or mild abdominal discomfort. Rare but serious effects such as allergic reactions, irregular heartbeat, or changes in blood pressure may occur.

Ondotyle Injection is indicated for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiotherapy, postoperative recovery, and gastrointestinal disturbances.

This injection should only be administered under the supervision of a qualified healthcare professional. Do not exceed the recommended dose. Discontinue use and consult a doctor immediately if adverse effects occur.

Store below 25°C in a cool, dry place, protected from light. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Ondansetron Hydrochloride IP 2mg + Ranitidine Injection in the PCD pharma franchise market?

This injectable combination has strong demand in the hospital and critical care segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on emergency care and gastro care portfolios.

Why should medical distributors include this injection in their product range?

Medical distributors and agencies can benefit from consistent hospital demand for management of nausea, vomiting, acidity, gastric irritation, gastritis, and post-operative gastric discomfort. Ondansetron helps control nausea and vomiting, while Ranitidine helps reduce stomach acid production, strengthening a comprehensive hospital care product portfolio.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for this product?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for this injectable combination with promotional support, monopoly rights, quality packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for this product?

Wholesalers and medical agencies benefit from strong hospital and institutional demand, emergency and post-operative care usage, reliable supply chain support, and good margins when partnering for this hospital care product.

How can I become a distributor or franchise partner for this injection?

Medical distributors, stockists, and wholesalers interested in this injectable combination can contact Cafoli LifeCare Pvt Ltd to discuss franchise opportunities, bulk supply requirements, pricing, and distribution support.